Medarex, Inc. (Nasdaq: MEDX) announced today that its partner MedImmune, Inc. has initiated a Phase I clinical trial of MEDI-545 for the potential treatment of psoriasis. MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R). [click link for full article]
More...